Form 4: Evolent Health Director Buys 10,000 Shares

Evolent Health Director Brendan B. Springstubb acquired 10,000 shares of Class A Common Stock at $3.8199 per share, increasing his direct beneficial ownership to 58,821 shares.

Summary

• Brendan B. Springstubb, a Director of Evolent Health, Inc. (EVH), purchased 10,000 shares of Class A Common Stock.
• The transaction occurred on November 18, 2025, at a price of $3.8199 per share.
• Following this purchase, Springstubb directly beneficially owns 58,821 shares of Evolent Health Class A Common Stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged acquisition.
• The reported beneficial ownership includes restricted stock units from previously filed Form 4s.

Sentiment

Score: 7

Explanation: The purchase of company stock by a director, especially under a pre-arranged plan, generally indicates confidence in the company's prospects, which is a positive signal for investors.

Positives

• A company director, Brendan B. Springstubb, purchased 10,000 shares of Class A Common Stock, which can signal confidence in the company's future prospects.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned acquisition rather than a reactive one.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Director Brendan B. Springstubb, a related party, acquired 10,000 shares of Class A Common Stock from the issuer.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive indicator of management's belief in the company's value, potentially influencing investor sentiment.

Key Dates

Recommendation

The purchase of 10,000 shares by a director signals confidence in Evolent Health's future. While a positive indicator, this single transaction alone does not warrant a 'buy' recommendation without further fundamental analysis of the company's financial performance, strategic outlook, and market conditions. It reinforces a 'hold' position for existing investors.

Keywords

Evolent Health, EVH, Insider Trading, Stock Purchase, Director, Brendan Springstubb, Form 4, SEC Filing, Equity Acquisition, Rule 10b5-1